Mirtazapina Flas (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Flas, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral formulation for oral use. It is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapina Flas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality manufacturing standards, reliable distribution across global markets, and comprehensive support for product registration and logistics.

Mirtazapine is indicated for major depressive disorder, a condition that affects mood, cognition and physical function.

- Major depressive disorder: reduces depressive symptoms, improves mood, sleep and overall functioning in adult patients.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Edema (swelling of the lower limbs)

Serious or Rare Side Effects: - Agranulocytosis (dangerously low white‑blood‑cell count) - Severe neutropenia - Hepatotoxicity (liver injury) - Seizures - Suicidal thoughts or behavior, especially early in treatment - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome)

Before initiating therapy, clinicians should assess patient history and monitor for specific risks.

- Pregnancy: Category C – weigh potential benefits against risks and consult obstetric guidance. - Breastfeeding: Use only if benefits outweigh potential infant exposure. - Elderly patients: Start at low dose and monitor for excessive sedation or falls. - Hepatic impairment: Dose adjustment may be required; monitor liver function tests. - Concomitant CNS depressants: Increase risk of sedation and respiratory depression. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation. - Anticholinergic agents: may exacerbate dry mouth and constipation. - Warfarin: monitor INR as mirtazapine may affect coagulation parameters.